Patricia Industries funds Laborie’s strategic acquisition of Urotronic
Laborie, a subsidiary within Patricia Industries, has entered an agreement to acquire the remaining 91 percent of Urotronic, a US medical technology company, including its OptilumeTM device for the treatment of benign prostatic hyperplasia (BPH). In 2020, Laborie entered into a strategic partnership with Urotronic, whereby Laborie acquired 9 percent of the company and two separate call options, one for OptilumeTM urethral strictures, and one for the acquisition of the remaining 91 percent of Urotronic, including OptilumeTM BPH. In early 2022, Laborie exercised its call option to